Powder: -20°C for 3 years | In solvent: -80°C for 1 year
EGFR-IN-8, a dual inhibitor targeting both EGFR and c-Met, shows potential as a promising candidate for further development in treating EGFR TKI-resistant NSCLC.
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
1 mg | 在庫あり | ¥ 27,000 | |||
5 mg | 在庫あり | ¥ 66,000 | |||
10 mg | 在庫あり | ¥ 110,000 | |||
25 mg | 在庫あり | ¥ 181,000 | |||
50 mg | 在庫あり | ¥ 248,000 | |||
100 mg | 在庫あり | ¥ 340,000 | |||
1 mL * 10 mM (in DMSO) | 在庫あり | ¥ 97,000 |
分子量 | 662.02 |
分子式 | C32H23ClF3N7O4 |
CAS No. | 2407957-87-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 8 mg/mL (12.08 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
EGFR-IN-8 2407957-87-1 Angiogenesis JAK/STAT signaling Tyrosine Kinase/Adaptors EGFR c-Met/HGFR inhibit Epidermal growth factor receptor EGFR IN 8 ErbB-1 HER1 Inhibitor EGFRIN8 inhibitor